Open AccessPharmacotherapy of inflammatory bowel diseases: efficacy performance and safety management
Author(s) -
И. Г. Бакулин,
Бакулин Игорь Геннадьевич,
M. I. Skalinskaya,
Скалинская Мария Игоревна,
И. В. Маев,
Маев Игорь Вениаминович,
Е. В. Сказываева,
Сказываева Екатерина Васильевна,
M. Zhuravleva,
Журавлева Мария Сергеевна,
L.B. Gaikovaya,
Гайковая Лариса Борисовна,
Н. В. Бакулина,
Бакулина Наталья Валерьевна,
А.И. Ермаков,
Ермаков Алексей Игоревич,
Ekaterina S. Alekseenko,
Алексеенко Екатерина Сергеевна,
K Ivanova,
Иванова Кристина Наполеоновна,
M. V. Solov’ev,
Соловьев Михаил Викторович
Publication year - 2021
Publication title -
terapevtičeskij arhiv
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.181
H-Index - 14
eISSN - 2309-5342
pISSN - 0040-3660
DOI - 10.26442/00403660.2021.08.200982
Subject(s) - medicine , ulcerative colitis , inflammatory bowel disease , pharmacotherapy , adverse effect , drug , inflammatory bowel diseases , disease , intensive care medicine , pharmacology
Treatment of inflammatory bowel diseases IBD (Crohns disease, ulcerative colitis) is aimed at achieving clinical, endoscopic and histological remission, minimizing surgical complications, and ensuring a normal quality of life. However, the use of medical treatment is potentially associated with various adverse events, among which infectious complications, malignant neoplasms, as well as myelotoxicity, hepatotoxicity, skin lesions and others. The risk of side effects depends on the type of drug therapy (5-aminosalicylates, thiopurines, biologicals, etc.), the duration of treatment, the presence of extra-intestinal manifestations, etc. The article provides an overview of data on both the effectiveness and frequency of various side effects of the main classes of drugs in IBD, presents methods of investigation which can predict the effectiveness and development of side effects, the implementation of which can be considered as a variant of personalized therapy in IBD.